Results For "0"

A Quantitative Systems Pharmacology Model to Study the Efficacy of Therapies for the Treatment of Autoimmune Disease Blog Post

This webinar is hosted by the International Society of Pharmacometrics (ISoP) Speakers:  Abstract: The development of therapeutic antagonists that target BAFF and APRIL to treat autoimmune disease is still in its…

Best Practices for a Successful eCTD Submission Blog Post

了解制药申办方在提交监管 eCTD 程序中遇到的常见陷阱以及解决这些问题的最佳实践。

What’s New in the Simcyp™ Simulator – from Regulatory Advances to New Modalities Blog Post

Already the most sophisticated technology for physiologically based pharmacokinetic modeling (PBPK), the Simcyp Simulator has added a range of new advances in its recently release (version 23). This webinar, hosted…

Case Study: Transforming Health Economics Communication for a Global Biopharmaceutical Company in Colombia Blog Post

探索赛诺菲哥伦比亚公司如何通过 BaseCase 革新卫生经济学沟通方式。

CERTAINTY by Certara 2024 | Teaser Blog Post

Transcript: The Certara community and interdisciplinary industry experts and scientists from model and form drug development bio simulation, clinical pharmacology, regulatory science, and software development come together for Certainty. Certara’s…

Certara Reports Fourth Quarter 2023 Financial Results Blog Post

Provides Full Year 2024 Financial Guidance PRINCETON, N.J.— 2024 年 2 月 29 日– Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal…

What is new in Phoenix 8.5? Blog Post

了解 Phoenix 8.5 版本的最新进展和增强功能。Watch the webinar to learn more…

Planning for a Successful EMA Policy 0070 Submission Blog Post

How to Navigate the FDA Landscape for an Orphan Drug Blog Post

罕见病是公共卫生领域的优先事项。FDA has launched several programs and a final guidance to address the unmet need for orphan drugs.

Dose Optimization Considerations for Targeted Radiation Therapies Blog Post

Eli Lilly 收购靶向放射治疗（TRT）公司 Point Biopharma，以及 Bristol Meyer Squibb 收购 RayzeBio 的交易，引发了投资者对该治疗领域的关注。A growing number…